Dr. Malik Slassi

Senior Vice President, Discovery Research

Dr. Slassi was the Founder, President and Chief Scientific Officer of Fluorinov Pharma Inc. acquired by Trillium in January 2016. With over 25 years of experience in the successful identification of small molecule drug candidates across multiple therapeutic areas including oncology, neurology and gastro-intestinal, Dr. Slassi has advanced over 16 drug candidates into late-stage preclinical and clinical development. Prior to founding Fluorinov, Dr. Slassi held high level positions at NPS Pharmaceuticals, Cascade Therapeutics, Allelix Biopharmaceuticals Inc., Boehringer Ingelheim Research Inc., and Rhône Poulenc. Dr. Slassi holds a Ph.D. in chemistry from the University of Claude Bernard, Lyon, France and completed his postdoctoral work in the Chemistry Department at the University of Montreal, Canada.